Overexpression of potassium channel ether à go-go1 in human osteosarcoma

Neoplasma

Volumn 59, Issue 2, 2012, Pages 207-215

  Wu, J ^a   Wu, X ^a   Lian, K ^a   Lin, B ^a   Guo, L ^a   Ding, Z ^a  

^a Orthopaedic Center of People s Liberation Army   (China)

Author keywords

Go go1; Human osteosarcoma; Human potassium channel ether; Immunohistochemistry; Polyclonal antibody

Indexed keywords

HYBRID PROTEIN; POTASSIUM CHANNEL HERG; KCNH1 PROTEIN, HUMAN; MESSENGER RNA; RECOMBINANT PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OSTEOCHONDROMA; OSTEOSARCOMA; PRESCHOOL CHILD; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; WESTERN BLOTTING; AGED; ANIMAL; BONE TUMOR; CELL STRAIN HEK293; CHANNEL GATING; DRUG EFFECT; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROGNOSIS; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ADOLESCENT; ADULT; AGED; ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CHILD; ETHER-A-GO-GO POTASSIUM CHANNELS; FLUORESCENT ANTIBODY TECHNIQUE; HEK293 CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; ION CHANNEL GATING; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS; RABBITS; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863845776     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_027     Document Type: Article

References (29)

1. WARMKE J, DRYSDALE R AND GANETZKY B. A distinct potassium channel polypeptide encoded by the Drosophila eag locus. Science 1991; 252: 1560-1562. http://dx.doi. org/10.1126/science.1840699
2. WARMKE JW AND GANETZKY B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994; 91: 3438-3442. http://dx.doi. org/10.1073/pnas.91.8.3438
3. BAUER CK AND SCHWARZ JR. Physiology of EAG K+ channels. J Membr Biol 2001; 182: 1-15. http://dx.doi. org/10.1007/s00232-001-0031-3
4. CAMACHO J, SÁNCHEZ A, STÜHMER W AND PARDO LA. Cytoskeletal interactions determine the electrophysiological properties of human EAG potassium channels. Pflugers Arch 2000; 441: 167-174. http://dx.doi.org/10.1007/s004240000420
5. FARIAS LM, OCAÑA DB, DÍAZ L, LARREA F, AVILACHÁVEZ E et al. Ether à go-go potassium channels as human cervical cancer markers. Cancer Res 2004; 64: 6996-7001. http://dx.doi.org/10.1158/0008-5472
6. OCCHIODORO T, BERNHEIM L, LIU JH, BIJLENGA P, SINNREICH M et al. Cloning of a human ether à go-go potassium channel expressed in myoblasts at the onset of fusion. FEBS Lett 1998; 434: 177-182. http://dx.doi.org/10.1016/S0014-5793(98)00973-9
7. MELLO DE QUEIROZ F, SUAREZ-KURTZ G, STÜHMER W AND PARDO LA. Ether à go-go potassium channel expression in soft tissue sarcoma patients. Mol Cancer 2006; 5:42. http://dx.doi.org/10.1186/1476-4598-5-42
8. DING XW, WANG XG, LUO HS, TAN SY, GAO S et al. Expression and prognostic roles of Eag1 in resected esophageal squamous cell carcinomas. Dig Dis Sci 2008; 53: 2039-2044. http://dx.doi.org/10.1007/s10620-007-0116-7
9. PARDO LA AND SÜHMER W. Eag1 as cancer target. Expert Opin Ther Targets 2008; 12: 837-843. doi:10.1517/14728222.12.7.837 http://dx.doi.org/10.1517/14728222.12.7.837
10. DAMRON TA, WARD WG AND STEWART A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base report. Clin Orthop Relat Res 2007; 459: 40-47. http://dx.doi.org/10.1097/BLO.0b013e318059b8c9
11. SLUGA M, WINDHAGER R, PFEIFFER M, OFNER P, LANG S et al. Osteosarcoma and Ewing's sarcoma-The most frequent malignant bone tumors in children-therapy and outcome. Z Orthop Ihre Grenzgeb 2002; 140: 652-655. http://dx.doi. org/10.1055/s-2002-36040
12. WITTIG JC, BICKELS J, PRIEBAT D, JELINEK J, KELLARGRANEY K et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 2002; 65: 1123-1132. http://dx.doi.org/10.1016/j.progpolymsci.2008.07.007
13. LAVERDIERE C, HOANG BH, YANG R, SOWERS R, QIN J et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005; 11: 2561-2567. http://dx.doi. org/10.1158/1078-0043.CCR-04-1089
14. URAKAWA H, NISHIDA Y, NAKASHIMA H, SHIMOYAMA Y, NAKAMURA S et al. Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 2009; 26: 1005-1012. http://dx.doi.org/10.1007/s10585-009-9290-7
15. WU PK, CHEN WM, CHEN CF, LEE OK, HAUNG CK et al. Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol 2009; 39: 514-522. http://dx.doi.org/10.1093/jjco/hyp057
16. SAKAMOTO A AND IWAMOTO Y. Current status and perspectives regarding the treatment of osteosarcoma: chemotherapy. Rev Recent Clin Trials 2008; 3: 228-231. http://dx.doi. org/10.2174/157488708785700267
17. MATSUURA N, OHNISHI A, ITOH Y, WAKASUGI E and TSUJIMOTO M. Immunohistochemistry in the diagnosis and treatment of breast cancer. Gan To Kagaku Ryoho 1996; 23: 24-29.
18. LUDWIG J, WESELOH R, KARSCHIN C, LIU Q, NETZER R et al. Cloning and functional expression of rat eag2, a new member of the ether-à-go-go family of potassium channels and comparison of its distribution with that of eag1. Mol Cell Neurosci 2000; 16: 59-70. http://dx.doi.org/10.1006/mcne.2000.0851
19. HEMMERLEIN B, WESELOH RM, MELLO DE QUEIROZ F, KNÖTGEN H, SÁNCHEZ A et al. Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer 2006; 5: 41 http://dx.doi.org/10.1186/1476-4598-5-41
20. CHEN Y, SÁNCHEZ A, RUBIO ME, KOHL T, PARDO LA et al. Functional K(v)10.1 channels localize to the inner nuclear membrane. PLoS One 2011; 6: e19527. http://dx.doi. org/10.1371/journal.pone.0019257
21. DING XW, LUO HS, JIN X, YAN JJ AND AI YW. Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines. Med Oncol 2007; 24: 345-350. http://dx.doi. org/10.1007/s12032-007-0015-y
22. OUSINGSAWAT J, SPITZNER M, PUNTHEERANURAK S, TERRACCIANO L, TORNILLO L et al. Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin Cancer RES 2007; 13: 824-831. http://dx.doi. org/10.1158/1078-0432
23. WADHWA S, WADHWA P, DINDA AK AND GUPTA NP. Differential expression of potassium ion channels in human renal cell carcinoma. Int Urol Nephrol 2009; 41: 251-257. http://dx.doi.org/10.1007/s11255-008-9459-z
24. GAVRILOVA-RUCH O, SCHÖNHERR K, GESSNER G, SCHÖNHERR R, KLAPPERSTÜCK T et al. Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Membr Biol 2002; 188: 137-149. http://dx.doi. org/10.1007/s00232-001-0181-3
25. PARDO LA, DEL CAMINO D, SÁNCHEZ A, ALVES F, BRÜGGEMANN A et al. Oncogenic potential of EAG K+ channels. EMBO J 1999; 18: 5540-5547. http://dx.doi. org/10.1093/emboj/18.20.5540
26. AGARWAL JR, GRIESINGER F, STÜHMER W AND PARDO LA. The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer 2010; 9: 18. http://dx.doi.org/10.1186/1476-4598-9-18
27. ASHER V, KHAN R, WARREN A, SHAW R, SCHALKWYK GV et al. The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol 2010; 5: 78. http://dx.doi.org/10.1186/1746-1596-5-78
28. CAMACHO J. Ether à go-go potassium channels and cancer. Cancer Lett 2006; 233: 1-9. http://dx.doi.org/10.1016/j.canlet.2005.02.016
29. ASHER V, SOWTER H, SHAW R, BALI A and KHAN R. Eag and HERG potassium channels as novel therapeutic targets in cancer. World J Surg Oncol 2010; 8: 113. http://dx.doi. org/10.1186/1477-7819-8-113